ATP13A1 Inhibitors
Chemical inhibitors of ATP13A1 can impede its function through various mechanisms that impact the protein's activity at the cellular level. Ouabain, a well-known inhibitor of Na+/K+ ATPases, can indirectly affect ATP13A1 by perturbing the ionic gradients crucial for its function, as ATP13A1 belongs to the P-type ATPase family and is dependent on these gradients for its ion transport activity. Similarly, Thapsigargin, which targets the SERCA pump, leads to disruptions in calcium homeostasis. Given that ATP13A1's activity might be modulated by calcium levels, alterations induced by Thapsigargin can lead to inhibition of ATP13A1. The specific inhibitor of V-ATPases, Bafilomycin A1, by disturbing proton gradients, can indirectly impact ATP13A1, which relies on such electrochemical gradients across membranes. Vanadate, by competing with ATP for binding to ATP13A1, can inhibit the protein's ATPase activity, essential for its function in transmembrane ion transport.
Oligomycin, which inhibits ATP synthase, reduces the overall cellular ATP concentration. As ATP13A1 requires ATP for its catalytic action, a reduction in ATP levels due to Oligomycin indirectly inhibits ATP13A1. Verapamil and Bepridil, both calcium channel blockers, alter calcium homeostasis, and these alterations can inhibit ATP13A1's function if it is regulated by intracellular calcium. Dicyclohexylcarbodiimide (DCCD) can inhibit ATP13A1 by reacting with carboxyl groups within the protein, potentially blocking its active site. Amiloride, by modifying ionic gradients, particularly Na+/H+ exchange, can indirectly inhibit ATP13A1, which may also be involved in maintaining these gradients. N-Ethylmaleimide and Iodoacetate, both of which modify cysteine residues, can inhibit ATP13A1 by affecting its structural integrity or the redox status, thus impacting the protein's overall activity within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Ouabain-d3 (Major) | sc-478417 | 1 mg | $506.00 | |||
Ouabain is a known inhibitor of Na+/K+ ATPases. ATP13A1 is a P-type ATPase; thus ouabain can indirectly inhibit ATP13A1 by disrupting the ionic gradients and cellular homeostasis that ATP13A1 relies on for its function. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin inhibits the SERCA pump, affecting calcium homeostasis. As ATP13A1 is implicated in ion transport, the disruption of intracellular calcium levels can indirectly inhibit ATP13A1's activity. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $96.00 $250.00 $750.00 $1428.00 | 280 | |
Bafilomycin A1 specifically inhibits V-ATPases. By disrupting proton gradients, it can indirectly affect ATP13A1's function as the protein is a transmembrane ATPase dependent on electrochemical gradients. | ||||||
Sodium metavanadate | 13718-26-8 | sc-251034 sc-251034A | 5 g 25 g | $31.00 $82.00 | 3 | |
Vanadate is a general inhibitor of ATPases. It inhibits ATP13A1 by potentially competing with ATP for binding to the active site, thereby inhibiting its ATPase activity. | ||||||
Oligomycin A | 579-13-5 | sc-201551 sc-201551A sc-201551B sc-201551C sc-201551D | 5 mg 25 mg 100 mg 500 mg 1 g | $175.00 $600.00 $1179.00 $5100.00 $9180.00 | 26 | |
Oligomycin inhibits ATP synthase, leading to reduced ATP levels. Since ATP13A1 requires ATP to function, oligomycin indirectly inhibits ATP13A1 by depleting its energy source. | ||||||
Verapamil | 52-53-9 | sc-507373 | 1 g | $367.00 | ||
Verapamil is a calcium channel blocker that alters calcium homeostasis. As ATP13A1 activity might be regulated by calcium, verapamil can indirectly inhibit ATP13A1 by altering its calcium-dependent regulatory mechanisms. | ||||||
DCC | 538-75-0 | sc-239713 sc-239713A | 25 g 100 g | $71.00 $204.00 | 3 | |
Dicyclohexylcarbodiimide (DCCD) reacts with carboxyl groups within ATPases, potentially inhibiting ATP13A1 by blocking its active site and preventing ATP hydrolysis necessary for its function. | ||||||
Bepridil | 64706-54-3 | sc-507400 | 100 mg | $1620.00 | ||
Bepridil is a calcium channel blocker that could affect ATP13A1 indirectly by disturbing the calcium homeostasis that is potentially important for ATP13A1's activity. | ||||||
Amiloride | 2609-46-3 | sc-337527 | 1 g | $290.00 | 7 | |
Amiloride is an inhibitor of Na+/H+ exchangers. By altering ionic gradients, amiloride can indirectly inhibit ATP13A1, which may rely on these gradients for its ion transport function. | ||||||
N-Ethylmaleimide | 128-53-0 | sc-202719A sc-202719 sc-202719B sc-202719C sc-202719D | 1 g 5 g 25 g 100 g 250 g | $22.00 $68.00 $210.00 $780.00 $1880.00 | 19 | |
N-Ethylmaleimide alkylates cysteine residues, which could modify critical disulfide bonds within ATP13A1, potentially inhibiting its structural integrity and function. | ||||||